These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3586701)

  • 21. Identification of the site at which phospholipase A2 neurotoxins localize to produce their neuromuscular blocking effects.
    Simpson LL; Lautenslager GT; Kaiser II; Middlebrook JL
    Toxicon; 1993 Jan; 31(1):13-26. PubMed ID: 8446959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Productive and non-productive binding of botulinum neurotoxin A to motor nerve endings are distinguished by its heavy chain.
    Daniels-Holgate PU; Dolly JO
    J Neurosci Res; 1996 May; 44(3):263-71. PubMed ID: 8723765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elimination of superfluous neuromuscular junctions in rat calf muscles recovering from botulinum toxin-induced paralysis.
    Hassan SM; Jennekens FG; Wieneke G; Veldman H
    Muscle Nerve; 1994 Jun; 17(6):623-31. PubMed ID: 8196705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ionic requirements for the neuromuscular blocking action of botulinum toxin: implications with regard to synaptic transmission.
    Simpson LL
    Neuropharmacology; 1971 Nov; 10(6):673-84. PubMed ID: 4331443
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins.
    Simpson LL; Coffield JA; Bakry N
    J Pharmacol Exp Ther; 1994 Apr; 269(1):256-62. PubMed ID: 8169833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of temperature upon paralyzing and myotoxic effects of bothropstoxin-I on mouse neuromuscular preparations.
    Cavalcante WL; Silva MD; Gallacci M
    Chem Biol Interact; 2005 Jan; 151(2):95-100. PubMed ID: 15698581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic denervation caused by botulinum neurotoxin as a model of a neuromuscular disease.
    Frangez R; Dolinsek J; Demsar F; Suput D
    Ann N Y Acad Sci; 1994 Mar; 710():88-93. PubMed ID: 8154764
    [No Abstract]   [Full Text] [Related]  

  • 28. [Botulinum neurotoxin].
    Poulain B
    Rev Neurol (Paris); 2010 Jan; 166(1):7-20. PubMed ID: 19846187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the action of botulinum neurotoxins A and E at cholinergic terminals.
    Washbourne P; Pellizzari R; Rossetto O; Bortoletto N; Tugnoli V; De Grandis D; Eleopra R; Montecucco C
    J Physiol Paris; 1998 Apr; 92(2):135-9. PubMed ID: 9782457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects in the mouse of nerve crush and regneration on the innervation of skeletal muscles paralysed by Clostridium botulinum toxin.
    Duchen LW
    J Pathol; 1970 Sep; 102(1):9-14. PubMed ID: 4926981
    [No Abstract]   [Full Text] [Related]  

  • 31. The binding of botulinum toxin to membrane lipids: phospholipids and proteolipid.
    Simpson LL; Rapport MM
    J Neurochem; 1971 Sep; 18(9):1761-7. PubMed ID: 4936887
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction.
    Kauffman JA; Way JF; Siegel LS; Sellin LC
    Toxicol Appl Pharmacol; 1985 Jun; 79(2):211-7. PubMed ID: 2988154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins.
    Simpson LL
    J Pharmacol Exp Ther; 1988 Jun; 245(3):867-72. PubMed ID: 2455038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetanus toxin blocks the neuromuscular transmission in vitro like botulinum A toxin.
    Habermann E; Dreyer F; Bigalke H
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Feb; 311(1):33-40. PubMed ID: 6245375
    [No Abstract]   [Full Text] [Related]  

  • 35. Botulinum Neurotoxins: Qualitative and Quantitative Analysis Using the Mouse Phrenic Nerve Hemidiaphragm Assay (MPN).
    Bigalke H; Rummel A
    Toxins (Basel); 2015 Nov; 7(12):4895-905. PubMed ID: 26610569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting.
    Adler S; Bicker G; Bigalke H; Bishop C; Blümel J; Dressler D; Fitzgerald J; Gessler F; Heuschen H; Kegel B; Luch A; Milne C; Pickett A; Ratsch H; Ruhdel I; Sesardic D; Stephens M; Stiens G; Thornton PD; Thürmer R; Vey M; Spielmann H; Grune B; Liebsch M
    Altern Lab Anim; 2010 Aug; 38(4):315-30. PubMed ID: 20822324
    [No Abstract]   [Full Text] [Related]  

  • 37. Recovery from botulinum neurotoxin poisoning in vivo.
    Keller JE
    Neuroscience; 2006 May; 139(2):629-37. PubMed ID: 16490322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals.
    Gansel M; Penner R; Dreyer F
    Pflugers Arch; 1987 Aug; 409(4-5):533-9. PubMed ID: 2888074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of stonefish (Synanceia trachynis) venom on murine and frog neuromuscular junctions.
    Kreger AS; Molgó J; Comella JX; Hansson B; Thesleff S
    Toxicon; 1993 Mar; 31(3):307-17. PubMed ID: 8470134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Botulinum neurotoxin type E: studies on mechanism of action and on structure-activity relationships.
    Simpson LL; Dasgupta BR
    J Pharmacol Exp Ther; 1983 Jan; 224(1):135-40. PubMed ID: 6294275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.